Top stories from the Proactive Investors UK newsroom.
Aquaculture specialist Benchmark (LON:BMK) has claimed a breakthrough that might increase genetic resistance to a major infection in tilapia. The company has identified a strain of DNA that can help the fish fight off the disease more effectively.
Polarean Imaging (LON:POLX) has received another order from a research customer for its MRI scanning technology. The University of Kansas Medical Center has ordered the kit, which means 25 polarisers are now either installed or on order.
Allergy Therapeutics (LON:AGY) has confirmed that sales this year will come in above previous expectations at £73.7m, which is growth of 8%. On current assumptions, Allergy added it should be also able to fund the Phase III hay fever vaccine trial planned to start next year by itself.
Reckitt Benckiser has paid US$1.4bn to settle a long-running investigation by the US federal authorities into how opioid dependency treatment Suboxone was sold and marketed. The business involved became Indivior when it was demerged from Reckitt in 2014.
Indivior itself meanwhile says Suboxone Film’s market share has been better than expected this year and revenues for 2019 are now expected to be between US$670mln and US$720mln. That is a 28% upgrade at the bottom end.